About this trial
Knee osteoarthritis (OA) is a chronic, painful disease associated with considerable morbidity, costs and disability. It is estimated that over a third of people aged over 60 have radiographic knee OA2 and over 50% of these with knee OA will go on to have a total knee replacement in their lifetime. At present there are no licensed treatments that alter disease progress and management is primarily concerned with symptom control to retain or improve joint function, although a trial of strontium ranelate showed promising results.
Eligibility criteria
Qualifiers
Primary osteoarthritis Patients recruited were between 30 to 60 years of age.
X-ray confirmed Kellgren-Lawrence grade II or III severity primary tibiofemoral OA according to the American College of Rheumatology criteria.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Celecoxib 200mg
- Metformin
Treatment groups
Sponsors and collaborators
Mostafa Bahaa
Lead sponsor
Tanta University
Sponsor institution